95 related articles for article (PubMed ID: 371798)
21. Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Berek JS; Markman M; Stonebraker B; Lentz SS; Adelson MD; DeGeest K; Moore D
Gynecol Oncol; 1999 Oct; 75(1):10-4. PubMed ID: 10502418
[TBL] [Abstract][Full Text] [Related]
22. Treatment of chronic lymphocytic leukemia and lymphosarcoma with a new chlorambucil ester of prednisolone (Leo 1031) (NSC-134087).
Aungst CW; Mittelman A; Murphy GP
J Surg Oncol; 1975; 7(6):457-60. PubMed ID: 1102806
[TBL] [Abstract][Full Text] [Related]
23. Prednisolone and chlorambucil therapy for idiopathic membranous nephropathy with progressive renal failure.
Warwick GL; Geddes CG; Boulton-Jones JM
Q J Med; 1994 Apr; 87(4):223-9. PubMed ID: 8208913
[TBL] [Abstract][Full Text] [Related]
24. Prednimustine in advanced breast cancer: a review.
Mouridsen HT
Semin Oncol; 1986 Mar; 13(1 Suppl 1):27-31. PubMed ID: 3513318
[TBL] [Abstract][Full Text] [Related]
25. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
26. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
27. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy.
Bruckner HW; Ratner LH; Cohen CJ; Wallach R; Kabakow B; Greenspan EM; Holland JF
Cancer Treat Rep; 1978 Jul; 62(7):1021-3. PubMed ID: 688244
[TBL] [Abstract][Full Text] [Related]
29. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results.
Coeffic D; Benhammouda A; Antoine EC; Rixe O; Paraiso D; Auclerc G; Nizri D; Renody N; Grapin JP; Mularoni E; Rattini E; Soubrane C; Weil M; Mortier N; Khayat D
Semin Oncol; 1996 Dec; 23(6 Suppl 15):5-8. PubMed ID: 8996589
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of carboplatin in patients with ovarian carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study.
Eisenhauer EA; Swenerton KD; Sturgeon JF; Fine S; O'Reilly SE
Cancer Treat Rep; 1986 Oct; 70(10):1195-8. PubMed ID: 3530446
[TBL] [Abstract][Full Text] [Related]
32. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
33. Remission induction with carboplatin-epirubicin-prednimustine followed by consolidation radiotherapy in advanced ovarian cancer.
Petru E; Pickel H; Heydarfadai M; Lahousen M
Int J Clin Pharmacol Res; 1992; 12(4):205-7. PubMed ID: 1297644
[TBL] [Abstract][Full Text] [Related]
34. Acute leukemia in advanced ovarian carcinoma after treatment with alkylating agents.
Sotrel G; Jafari K; Lash AF; Stepto RC
Obstet Gynecol; 1976 Jan; 47(1):67S-71S. PubMed ID: 1061006
[TBL] [Abstract][Full Text] [Related]
35. Cancer of the ovary: a summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital.
Wiltshaw E; Subramarian S; Alexopoulos C; Barker GH
Cancer Treat Rep; 1979; 63(9-10):1545-8. PubMed ID: 387225
[TBL] [Abstract][Full Text] [Related]
36. Leo 1031 (NSC-134087) in gynecologic malignancies.
Lele SB; Piver MS; Barlow JJ; Murphy GP
Oncology; 1978; 35(3):101-2. PubMed ID: 673313
[TBL] [Abstract][Full Text] [Related]
37. Prednimustine treatment in malignant lymphomas.
Szántó I; Fleischmann T; Eckhardt S
Oncology; 1989; 46(4):205-7. PubMed ID: 2662086
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of Prednimustine. Leo-1031 (NSC-134087) in acute non-lymphocytic leukemia.
Juul K; Sørensen P; Pedersen-Bjergaard J; Jensen MK
Scand J Haematol; 1979 Nov; 23(5):388-92. PubMed ID: 396664
[TBL] [Abstract][Full Text] [Related]
39. Prednimustine therapy for advanced prostatic cancer.
Catane R; Kaufman JH; Madajewicz S; Mittelman A; Murphy GP
Br J Urol; 1978 Feb; 50(1):29-32. PubMed ID: 630199
[TBL] [Abstract][Full Text] [Related]
40. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents.
Pedersen-Bjergaard J; Hansen MM; Geisler CH; Nissen NI
Acta Med Scand; 1980; 207(3):215-20. PubMed ID: 6989170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
